Brainstorm Cell Therapeutics INC.: directors' dealings · United States · SEC (Form 4)

About Brainstorm Cell Therapeutics INC.

BrainStorm Cell Therapeutics Inc. (BCLI) is a U.S.-listed biotechnology company traded on the NASDAQ in the United States. The company is focused on developing autologous cellular therapies for neurodegenerative diseases, with a long-standing emphasis on amyotrophic lateral sclerosis (ALS) and broader interest in other neurological indications that remain underserved. On its official website, BrainStorm describes NurOwn® as its core platform: an investigational autologous MSC-NTF cell therapy that is not FDA approved. ([brainstorm-cell.com](https://brainstorm-cell.com/)) The company has a long operating history in biotechnology and a corporate footprint tied to both the United States and Israel. SEC filings indicate that BrainStorm was originally incorporated in Washington state in 2000 before evolving into its current Delaware structure. Its business and scientific development have also been closely associated with Israel over time. BrainStorm’s principal executive offices are located at 1325 Avenue of Americas, 28th Floor, New York City, NY 10019. ([annualreports.com](https://www.annualreports.com/HostedData/AnnualReportArchive/b/NASDAQ_BCLI_2012.pdf?utm_source=openai)) From a business-model perspective, BrainStorm is essentially a clinical-stage, precommercial biotech whose value proposition is concentrated in one lead platform. NurOwn aims to produce MSC-NTF cells intended to modulate neuroinflammation and support neuronal survival in serious neurodegenerative conditions. The company has also disclosed work on an exosome-based platform and related intellectual-property efforts, which suggests a broader regenerative-medicine ambition, although the company remains primarily driven by its neurology pipeline today. ([ir.brainstorm-cell.com](https://ir.brainstorm-cell.com/2026-02-26-Brainstorm-Cell-Therapeutics-Secures-Second-1-Million-Strategic-Placement-Total-2-Million-Raised-In-February?utm_source=openai)) In competitive terms, BrainStorm is a niche player rather than a scale leader. It competes against larger pharmaceutical companies and better-capitalized biotech peers in the ALS and neurodegeneration space, so its differentiation depends on science, clinical data, regulatory execution, and capital access. Its competitive standing is therefore binary in nature: success would likely require meaningful clinical and regulatory progress, while setbacks would keep it in the category of high-risk development-stage companies. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1137883/000110465926062648/bcli-20260331x10q.htm)) Recent corporate updates show that management remains focused on advancing the planned Phase 3 ENDURANCE study of NurOwn in ALS. In its May 15, 2026 first-quarter update, BrainStorm said site activation and regulatory engagement were progressing, while also noting that financing remains necessary to move into manufacturing and enrollment phases. In February 2026, the company announced two strategic placements totaling $2 million, underscoring both continued investor interest and ongoing balance-sheet pressure. For equity investors, that combination is important: the story is still driven by pipeline execution, but dilution and financing risk remain central to the investment case. ([ir.brainstorm-cell.com](https://ir.brainstorm-cell.com/2026-05-15-BrainStorm-Cell-Therapeutics-Announces-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update))